^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Perjeta (pertuzumab)

    i
    Other names: RG1273, rhuMAb 2C4 , R 1273, R-1273, R1273, RG 1273, rhuMab2C4, Ro 436-8451/F01, RO-4368451-F01, RO4368451, rhuMab-2C4
    Company:
    Roche
    Drug class:
    HER2 dimerization inhibitor
    Related drugs:
    1d
    Cost-effectiveness analysis of tucatinib plus trastuzumab versus pertuzumab plus trastuzumab for chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or metastatic colorectal cancer. (PubMed, Expert Rev Pharmacoecon Outcomes Res)
    Tucatinib plus trastuzumab was cost-effective if its price was the same as lapatinib for chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or metastatic CRC from the perspective of healthcare payers in China. Our exploratory result could provide a reference for clinical application of tucatinib plus trastuzumab when they are correctly interpreted.
    Journal • HEOR • Cost-effectiveness
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive • RAS wild-type • RAS wild-type + HER-2 positive • HER-2 positive + RAS wild-type
    |
    Herceptin (trastuzumab) • lapatinib • Perjeta (pertuzumab) • Tukysa (tucatinib)
    3d
    Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR) (clinicaltrials.gov)
    P2, N=720, Recruiting, Canadian Cancer Trials Group | Trial primary completion date: Jan 2026 --> Dec 2026
    Trial primary completion date • Tumor mutational burden • Pan tumor
    |
    BRAF (B-raf proto-oncogene)
    |
    Opdivo (nivolumab) • Herceptin (trastuzumab) • Lynparza (olaparib) • Xalkori (crizotinib) • erlotinib • Yervoy (ipilimumab) • Ibrance (palbociclib) • dasatinib • Zelboraf (vemurafenib) • sunitinib • Perjeta (pertuzumab) • Cotellic (cobimetinib) • bosutinib • Tukysa (tucatinib) • temsirolimus • axitinib • Erivedge (vismodegib)
    3d
    Exceptional and Durable Complete Response to Ado-Trastuzumab Emtansine in HER2-Positive Metastatic Breast Cancer: A Case Report. (PubMed, Cureus)
    She received first-line chemotherapy with trastuzumab, pertuzumab, and docetaxel, followed by maintenance anti-HER2 therapy and surgery for local disease control. This case may represent an exceptional response to T-DM1 and highlights the potential for durable complete remission in selected patients with HER2-positive metastatic breast cancer. Further investigation is warranted to identify predictive factors for exceptional responses and to determine optimal treatment duration.
    Journal
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive • HER-2 overexpression • EGFR positive • HER-2 positive + HER-2 overexpression
    |
    docetaxel • Perjeta (pertuzumab) • Kadcyla (ado-trastuzumab emtansine)
    5d
    A Phase III Study of KN026 in Combination With HB1801 as Adjuvant Therapy for Resectable HER2-Positive Breast Cancer (clinicaltrials.gov)
    P3, N=1800, Not yet recruiting, Shanghai JMT-Bio Inc.
    New P3 trial
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive
    |
    Herceptin (trastuzumab) • carboplatin • docetaxel • Perjeta (pertuzumab) • doxorubicin hydrochloride • cyclophosphamide • epirubicin • anbenitamab (KN026)
    5d
    NATASHA: Study of HER2 Directed Dendritic Cell (DC1) Vaccine + Weekly Paclitaxel, Trastuzumab & Pertuzumab (clinicaltrials.gov)
    P2, N=53, Recruiting, H. Lee Moffitt Cancer Center and Research Institute | Trial completion date: Sep 2026 --> Sep 2027 | Trial primary completion date: Sep 2026 --> Feb 2027
    Trial completion date • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    Herceptin (trastuzumab) • Perjeta (pertuzumab) • albumin-bound paclitaxel • HER-2 pulsed DC1
    10d
    IBI354 With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (clinicaltrials.gov)
    P3, N=540, Recruiting, Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HR positive
    |
    Herceptin (trastuzumab) • paclitaxel • docetaxel • Perjeta (pertuzumab) • IBI-354
    10d
    A Phase 1 Trial of ZN-A-1041 Enteric Capsules or Combination in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=210, Active, not recruiting, Hoffmann-La Roche | Trial completion date: Jul 2026 --> Jul 2027 | Trial primary completion date: Jul 2026 --> Jul 2027
    Trial completion date • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive
    |
    Perjeta (pertuzumab) • Kadcyla (ado-trastuzumab emtansine) • Enhertu (fam-trastuzumab deruxtecan-nxki) • Phesgo (pertuzumab/trastuzumab/hyaluronidase-zzxf) • perzebertinib (RG6596)
    10d
    TOP-REAL: Trastuzumab Deruxtecan in First-Line HER2-Positive Metastatic Breast Cancer With Proactive Toxicity Management (clinicaltrials.gov)
    P2, N=300, Recruiting, SOLTI Breast Cancer Research Group | Not yet recruiting --> Recruiting
    Enrollment open • Adverse events • Real-world evidence
    |
    PGR (Progesterone receptor)
    |
    HER-2 positive
    |
    Perjeta (pertuzumab) • Enhertu (fam-trastuzumab deruxtecan-nxki)
    11d
    Extracellular Fluid Changes During Neoadjuvant Chemotherapy (clinicaltrials.gov)
    P=N/A, N=111, Completed, Florence Nightingale Hospital, Istanbul | Active, not recruiting --> Completed
    Trial completion
    |
    Perjeta (pertuzumab) • cyclophosphamide
    11d
    The Role of HER2 and RANK in Breast Cancer and New Therapeutic Approaches With Denosumab, Anti-HER2 Antibodies and Immunotherapy. (PubMed, J Cell Mol Med)
    This study aimed to evaluate the effectiveness of a triple-targeting regimen-Denosumab (D), Pertuzumab (P) and Trastuzumab (T)-for HER2-positive (HER2+) BC, and to assess the added value of immune checkpoint inhibitors (ICIs)...Additional analyses showed elevated signal transducer and activator of transcription 3 (STAT3) expression in HER2- tissues and higher mechanistic target of rapamycin (mTOR) expression in HER2- compared to HER2+ samples. Importantly, three-dimensional (3D) cell culture experiments demonstrated that adding ICIs (Nivolumab (N) and Ipilimumab (I)) to the triple-targeting regimen further reduced cell viability in HER2+ BC cells. These results underscore the pivotal role of the RANK-receptor activator of NF-κB ligand (RANKL) axis in tumour growth and immune regulation, supporting the use of triple-targeting therapy and suggesting enhanced benefits with the inclusion of ICIs to potentially overcome therapeutic resistance in HER2+ BC.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    mTOR (Mechanistic target of rapamycin kinase) • STAT3 (Signal Transducer And Activator Of Transcription 3) • TNFRSF11A (TNF Receptor Superfamily Member 11a)
    |
    HER-2 positive • HER-2 negative • HER-2 expression
    |
    Opdivo (nivolumab) • Herceptin (trastuzumab) • Yervoy (ipilimumab) • Perjeta (pertuzumab) • sirolimus • Prolia (denosumab)
    13d
    SOLTI-2402: Patient-Centered Study of T-DXd in Metastatic HER2-Positive Breast Cancer with Real-Life Side Effect Management (2025-521805-41-00)
    P2/3, N=300, Recruiting, Solti Group | Not yet recruiting --> Recruiting
    Enrollment open • Adverse events • Real-world evidence
    |
    PGR (Progesterone receptor)
    |
    HER-2 positive
    |
    Perjeta (pertuzumab) • Enhertu (fam-trastuzumab deruxtecan-nxki)
    15d
    STOP-HER2: Stopping Trastuzumab in HER2+ MBC (clinicaltrials.gov)
    P2, N=82, Active, not recruiting, Dana-Farber Cancer Institute | Trial completion date: Feb 2036 --> Jun 2036 | Trial primary completion date: Feb 2026 --> Jun 2026
    Trial completion date • Trial primary completion date
    |
    ER (Estrogen receptor)
    |
    HER-2 positive • ER positive • HER-2 negative • ER negative • HER-2 negative + ER positive
    |
    Herceptin (trastuzumab) • Perjeta (pertuzumab)